Stemline Therapeutics (STML) Misses Q1 EPS by 1c

Stemline Therapeutics (NASDAQ: STML) reported Q1 EPS of ($0.46), $0.01 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $121.4 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c